Compare Quest Diagnostics Inc (DGX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global X SuperDividend ETF — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Global X SuperDividend ETF trades at $23.82 (market cap $1.17B). The key difference: Quest Diagnostics Inc is far larger — about 21.8× Global X SuperDividend ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Global X SuperDividend ETF for 47 Days on average.
| DGX | SDIV | |
|---|---|---|
Market Cap | $25.48B | $1.17B |
Volume | 941,866 | 387,692 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $26.34 |
52-Week Low | $173.49 | $22.90 |
Typical Hold Time | 56 Days | 47 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.
Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
